Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors-Reference-Cited by-同舟云学术

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Published:2019-02-15 Issue:11 Volume:25 Page:3220-3228
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Jung Kyung Hae,LoRusso Patricia,Burris Howard,Gordon Michael,Bang Yung-Jue,Hellmann Matthew D.^ORCID,Cervantes Andrés^ORCID,Ochoa de Olza Maria,Marabelle Aurelien,Hodi F. Stephen,Ahn Myung-Ju,Emens Leisha A.,Barlesi Fabrice,Hamid Omid,Calvo Emiliano,McDermott David,Soliman Hatem,Rhee Ina,Lin Ray,Pourmohamad Tony,Suchomel Julia,Tsuhako Amy,Morrissey Kari,Mahrus Sami,Morley Roland,Pirzkall Andrea,Davis S. Lindsey

Funder

N/A

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations;Frontiers in Immunology;2024-09-03

2. Unlocking the potential: Targeting metabolic pathways in the tumor microenvironment for Cancer therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

3. Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies;International Journal of Nanomedicine;2024-08

4. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302);BMC Cancer;2024-07-25

5. Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study;BMC Cancer;2024-07-25